The chief function of the Neuropathology Core (NC) is to provide state of the art diagnostic services, to set up and maintain a collection of optimally prepared brain samples, and to supply samples for cutting edge research to investigators of the Center, affiliated Centers, and to outside neuroscientists conducting research into neurodegenerative diseases. Because humans are the only known species to naturally develop Alzheimer disease (AD) or related illnesses, the availability of carefully prepared postmortem samples is essenfial despite the existence of valuable transgenic animal models. Thus, human fissue-dependent studies require that the diagnostic categorization of samples of interest is as accurate as possible. This tissue must be made available quickly following the receipt of a request to enhance laboratory efficiency and productivities. Therefore, the specific aims of NC are: 1. To establish an accurate diagnosis on all brains obtained for the Center including clinico-pathological interpretations of the findings, which are recorded within two standardized reports;a) a text-based for clinicians and medical files, and b) a quantification-based report. The quantificafion-based report provides data to the Clinical Care / Data Management, and to the National Alzheimer's Coordinafing Committee (NACC) in compliance with National Institute on Aging (NIA) requirements. Furthermore, it is used for identifying the samples in storage with variables matching those specified by requestors;2. To obtain brain samples for tissue-dependent fresh frozen studies with or without requirement of cellular morphology preservation, which are ready for immediate disbursement once categorized;and formalin fixed samples;3. To organize the collecfion of samples, maintain it safely, and select among the samples in storage the ones that best match the requirement of a specific study with subsequent distribution within five working days from the time the receipt of the request;4. To teach clinicians, trainees, and neuroscientists the neuropathology of the demenfias, and to assist in correlating findings made in transgenic animal models with those usually occurring in the human brains;and 5. To cooperate with other Centers including the Nafional Institute of Neurological Disorders and Stroke (NINDS) supported Udall Center.
Defining the changes underiying dementias is prerequisite for knowing how to prevent them. Therefore, brains of individuals who died at different stage of the demenfia, and recording the type, extend, and distribufion of the changes must be achieved to opfimize the specificity of samples desfined for basic research including fissue-dependent investigations aiming at disclosing the causes of dementias.
|Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71|
|Zhou, Zilu; Wang, Weixin; Wang, Li-San et al. (2018) Integrative DNA copy number detection and genotyping from sequencing and array-based platforms. Bioinformatics 34:2349-2355|
|Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25|
|Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169|
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
|Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487|
|Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360|
|Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340|
|Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872|
|Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146|
Showing the most recent 10 out of 640 publications